Inactive Instrument

Press Releases BioLineRx Ltd. TEL AVIV STOCK EXCHANGE

Equities

BLRX

IL0011015182

Press Releases

Unlock all the news: Be the first to know and act before the market!

BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapy Applications in Sickle Cell Disease	May. 31	AQ
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates	May. 29	AQ
BioLineRx : Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates	May. 28	PU
BioLineRx to Report First Quarter 2024 Results on May 28, 2024	May. 22	PR
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification	May. 20	AQ
BioLineRx : Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024	May. 06	PU
BioLineRx : Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting	Apr. 17	PU
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement	Apr. 10	PR
BioLineRx Announces $6 Million Registered Direct Offering	Apr. 02	AQ
BioLineRx : Form 20-F/A (Amendment No. 1	Mar. 28	PU
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates	Mar. 27	AQ
BioLineRx : Annual Report on Form 20-F FOR 2023	Mar. 26	PU
BioLineRx : Report of Periodic or Interim Report	Mar. 26	PU
BioLineRx : Reports 2023 Financial Results and Recent Corporate and Portfolio Updates	Mar. 26	PU
BioLineRx to Report 2023 Annual Financial Results on March 26, 2024	Mar. 20	PR
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production	Mar. 04	PR
BioLineRx : FORM F-3-REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933	Dec. 31	PU
BioLineRx : FORM S-8-registration of Ordinary Shares to be issued under the Plan	Dec. 31	PU
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease	Dec. 21	PR
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates	Nov. 21	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases BioLineRx Ltd. TEL AVIV STOCK EXCHANGE

Equities

BLRX

IL0011015182

Press Releases

Filters